A 28 Day Parallel Group Study to Assess the Effects of RDN-929

NCT03963973 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Participants no longer receiving intervention

Conditions

Healthy

Interventions

DRUG: RDN-929 oral capsule
DRUG: Placebo oral capsule

Sponsor

Alkermes, Inc.